메뉴 건너뛰기




Volumn 42, Issue SUPPL. 1, 1997, Pages

Cognition-enhancing drugs in dementia: A guide to the near future

Author keywords

Cognition; Cognitive enhancers; Dementia; Drug therapy; Human

Indexed keywords

ALAPROCLATE; BESIPIRDINE; CERANAPRIL; CHOLINE; CYCLOSERINE; DEFEROXAMINE; DESMOPRESSIN; DIHYDROERGOTOXINE MESILATE; ESTRADIOL; GINKGO BILOBA EXTRACT; INDOMETACIN; LEVACECARNINE; LINOPIRDINE; MILACEMIDE; NALOXONE; NALTREXONE; NICERGOLINE; NIMODIPINE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; POSATIRELIN; PROPENTOFYLLINE; PROTIRELIN; PYRITINOL; SELEGILINE; TACRINE; TENILOXAZINE; UNINDEXED DRUG; VINPOCETINE;

EID: 0030757246     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (29)

References (190)
  • 1
    • 84937174490 scopus 로고
    • Pathophysiology of the Alzheímer's syndrome
    • Blass JP. Pathophysiology of the Alzheímer's syndrome. Neurology 1993;43(4 Suppl):25S-38S.
    • (1993) Neurology , vol.43 , Issue.4 SUPPL.
    • Blass, J.P.1
  • 2
    • 0027761432 scopus 로고
    • Neurochemical pathology and therapeutic strategies in degenerative dementia
    • Perry EK, Perry RH. Neurochemical pathology and therapeutic strategies in degenerative dementia. International Review of Psychiatry 1993;5:363-80.
    • (1993) International Review of Psychiatry , vol.5 , pp. 363-380
    • Perry, E.K.1    Perry, R.H.2
  • 3
    • 0028238408 scopus 로고
    • Emerging drugs for Alzheimer's disease: Mechanisms of action and prospects for cognitive enhancing medications
    • Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1904;78:911-34.
    • (1904) Med Clin North Am , vol.78 , pp. 911-934
    • Schneider, L.S.1    Tariot, P.N.2
  • 4
    • 1842283971 scopus 로고
    • Neurobiology and treatment of dementia
    • Salzman C, editor. Baltimore: Williams & Wilkins
    • Tariot PN. Neurobiology and treatment of dementia. In: Salzman C, editor. Clinical geriatric psychopharmacology. Baltimore: Williams & Wilkins; 1992. p 277-99.
    • (1992) Clinical Geriatric Psychopharmacology , pp. 277-299
    • Tariot, P.N.1
  • 6
    • 0028722665 scopus 로고
    • Therapy of Alzheimer disease: Symptomatic or neuroprotective?
    • Giacobini E. Therapy of Alzheimer disease: symptomatic or neuroprotective? J Neural Transm 1994;Suppl 43:211S-2I7S.
    • (1994) J Neural Transm , Issue.43 SUPPL.
    • Giacobini, E.1
  • 7
    • 0026788495 scopus 로고
    • Clinical trials in cognitive impairment in the elderly
    • Forette F, Panisset M, Boller F. Clinical trials in cognitive impairment in the elderly. Aging 1992;4:239-50.
    • (1992) Aging , vol.4 , pp. 239-250
    • Forette, F.1    Panisset, M.2    Boller, F.3
  • 8
    • 0025377720 scopus 로고
    • Keynote lecture 1: Problems in the search for cognitive enhancers
    • Hollister LE. Keynote lecture 1: problems in the search for cognitive enhancers. Pharmacopsychiatry 1990;23(Suppl):33S-36S.
    • (1990) Pharmacopsychiatry , vol.23 , Issue.SUPPL.
    • Hollister, L.E.1
  • 9
    • 0026708890 scopus 로고
    • Proof of efficacy of nootropics for the indication "dementia" (phase III)-recommendations
    • Menges K. Proof of efficacy of nootropics for the indication "dementia" (phase III)-recommendations. Pharmacopsychiatry 1992;25:126-35.
    • (1992) Pharmacopsychiatry , vol.25 , pp. 126-135
    • Menges, K.1
  • 10
    • 0028852890 scopus 로고
    • A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders
    • Minami M, Arai H, Takahashi T, Kimura M, Noguchi I, Suzuki T, and others. A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:59-64.
    • (1995) Prog Neuropsychopharmacol Biol Psychiatry , vol.19 , pp. 59-64
    • Minami, M.1    Arai, H.2    Takahashi, T.3    Kimura, M.4    Noguchi, I.5    Suzuki, T.6
  • 11
    • 0029101130 scopus 로고
    • Clinical pharmacokinetics of drugs for Alzheimer's disease
    • Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet 1995;29:110-29.
    • (1995) Clin Pharmacokinet , vol.29 , pp. 110-129
    • Parnetti, L.1
  • 12
    • 0027941873 scopus 로고
    • Memory disorders: Novel treatments, clinical perspective
    • Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci 1994;55:2189-94.
    • (1994) Life Sci , vol.55 , pp. 2189-2194
    • Pepeu, G.1
  • 13
    • 0027058349 scopus 로고
    • Neuropsychological factors in mental disorders and their treatments: Measurement and interpretation of changes in memory in response to drug treatment
    • Weingartner H, Eckardt M, Molchan S, Sunderland T, Wolkowitz O. Neuropsychological factors in mental disorders and their treatments: measurement and interpretation of changes in memory in response to drug treatment. Psychopharmacol Bull 1992;28:331-40.
    • (1992) Psychopharmacol Bull , vol.28 , pp. 331-340
    • Weingartner, H.1    Eckardt, M.2    Molchan, S.3    Sunderland, T.4    Wolkowitz, O.5
  • 15
    • 0028897914 scopus 로고
    • Canadian guidelines for the development of antidementia therapies: A conceptual summary
    • Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 1995;22(1):62-71.
    • (1995) Can J Neurol Sci , vol.22 , Issue.1 , pp. 62-71
    • Mohr, E.1    Feldman, H.2    Gauthier, S.3
  • 17
    • 0029933157 scopus 로고    scopus 로고
    • Ethical concerns in the use of palliative drug treatment for Alzheimer's disease
    • Filley CM, Chapman MM, Dubovsky SL. Ethical concerns in the use of palliative drug treatment for Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8:202-5.
    • (1996) J Neuropsychiatry Clin Neurosci , vol.8 , pp. 202-205
    • Filley, C.M.1    Chapman, M.M.2    Dubovsky, S.L.3
  • 19
    • 0027515763 scopus 로고
    • Desferrioxamine and Alzheimer's disease: Video home behavior assessment of clinical course and measures of brain aluminum
    • McLachlan DR, Smith WL, Kruck TP. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther Drug Monit 1993;15:602-7.
    • (1993) Ther Drug Monit , vol.15 , pp. 602-607
    • McLachlan, D.R.1    Smith, W.L.2    Kruck, T.P.3
  • 20
    • 0022261647 scopus 로고
    • Chelatíon therapy: Unproved modality in the treatment of Alzheimer-type dementia
    • Cardelli MB, Russell M, Bagne CA, Pomara N. Chelatíon therapy: unproved modality in the treatment of Alzheimer-type dementia. J Am Geriatr Soc 1985;33:548-51.
    • (1985) J Am Geriatr Soc , vol.33 , pp. 548-551
    • Cardelli, M.B.1    Russell, M.2    Bagne, C.A.3    Pomara, N.4
  • 24
    • 0025320360 scopus 로고
    • Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia
    • Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Society of Biological Psychiatry 1990;27:1133-42.
    • (1990) Society of Biological Psychiatry , vol.27 , pp. 1133-1142
    • Tollefson, G.D.1
  • 25
    • 0025977499 scopus 로고
    • Mid-term treatment of dementia with nimodipine: European Congress on Geriatric Treatment (1990, Catania, Italy)
    • Schinco P. Mid-term treatment of dementia with nimodipine: European Congress on Geriatric Treatment (1990, Catania, Italy). Archives of Gerontology & Geriatrics 1991;(2 Suppl):169S-172S.
    • (1991) Archives of Gerontology & Geriatrics , Issue.2 SUPPL.
    • Schinco, P.1
  • 26
    • 0027135596 scopus 로고
    • Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia
    • Fischhof PK. Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia. Methods Find Exp Clin Pharmacol 1993;15:549-55.
    • (1993) Methods Find Exp Clin Pharmacol , vol.15 , pp. 549-555
    • Fischhof, P.K.1
  • 29
    • 0022646038 scopus 로고
    • Double-blind randomized controlled study of phosphatidylserine in senile demented patients
    • Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand 1986;73:136-40.
    • (1986) Acta Neurol Scand , vol.73 , pp. 136-140
    • Delwaide, P.J.1    Gyselynck-Mambourg, A.M.2    Hurlet, A.3    Ylieff, M.4
  • 30
    • 0023931072 scopus 로고
    • Phosphatidylserine in the treatment of Alzheimer's disease: Results of a multicenter study
    • Amaducci L, the SMID Group. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull 1988;24:130-4.
    • (1988) Psychopharmacol Bull , vol.24 , pp. 130-134
    • Amaducci, L.1
  • 31
  • 33
    • 0026872682 scopus 로고
    • Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type
    • Engel RR, Satzger W, Gunther W, Kathmann N, Bove D, Gerke S, and others. Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992;2:149-55.
    • (1992) Eur Neuropsychopharmacol , vol.2 , pp. 149-155
    • Engel, R.R.1    Satzger, W.2    Gunther, W.3    Kathmann, N.4    Bove, D.5    Gerke, S.6
  • 34
    • 0024149141 scopus 로고
    • Multicenter clinical placebo-controlled study with acetyl-1-carnitine (LAC) in the treatment of mildly demented elderly patients
    • Cucínotta D, Passeri M, Ventura S, Iannuccelli M, Senin U, Bonati PA, and others. Multicenter clinical placebo-controlled study with acetyl-1-carnitine (LAC) in the treatment of mildly demented elderly patients. Drug Development Research 1988;14:213-6.
    • (1988) Drug Development Research , vol.14 , pp. 213-216
    • Cucínotta, D.1    Passeri, M.2    Ventura, S.3    Iannuccelli, M.4    Senin, U.5    Bonati, P.A.6
  • 35
    • 0013625850 scopus 로고
    • Peripheral cholinergic changes and pharmacological aspects in Alzheimer's disease
    • Giacobini E, Becker R, editors. New York: Taylor and Francis
    • Ravizza L, Ferrero P, Eva C, Rocca P, Tarenzi L, Benna P. Peripheral cholinergic changes and pharmacological aspects in Alzheimer's disease. In: Giacobini E, Becker R, editors. Current research in Alzheimer therapy. New York: Taylor and Francis; 1988. p 355-63.
    • (1988) Current Research in Alzheimer Therapy , pp. 355-363
    • Ravizza, L.1    Ferrero, P.2    Eva, C.3    Rocca, P.4    Tarenzi, L.5    Benna, P.6
  • 36
    • 0025032370 scopus 로고
    • Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia
    • Campi N, Todeschini GP, Scarzella L. Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 1990;12:306-14.
    • (1990) Clin Ther , vol.12 , pp. 306-314
    • Campi, N.1    Todeschini, G.P.2    Scarzella, L.3
  • 37
    • 0024786493 scopus 로고
    • Double-blind, placebo controlled study of acetyl-1-carnitine in patients with Alzheimer's dementia
    • Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo controlled study of acetyl-1-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;11:638-47.
    • (1990) Curr Med Res Opin , vol.11 , pp. 638-647
    • Rai, G.1    Wright, G.2    Scott, L.3    Beston, B.4    Rest, J.5    Exton-Smith, A.N.6
  • 38
    • 0026460074 scopus 로고
    • Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease
    • Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, and others. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-41.
    • (1992) Arch Neurol , vol.49 , pp. 1137-1141
    • Sano, M.1    Bell, K.2    Cote, L.3    Dooneief, G.4    Lawton, A.5    Legler, L.6
  • 42
    • 0028141762 scopus 로고
    • Overview of clinical trials of hydergine in dementia
    • Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787-98.
    • (1994) Arch Neurol , vol.51 , pp. 787-798
    • Schneider, L.S.1    Olin, J.T.2
  • 43
    • 0024594024 scopus 로고
    • Nicergoline in mild to moderate dementia: A multicenter, double-blind, placebo-controlled study
    • International Symposium on Alzheimer's Disease (1987, Amsterdam, Netherlands)
    • Battaglia A, Bruni G, Ardia A, Sacchetti G. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. International Symposium on Alzheimer's Disease (1987, Amsterdam, Netherlands). J Am Gerìatr Soc 1989;37:295-302.
    • (1989) J Am Gerìatr Soc , vol.37 , pp. 295-302
    • Battaglia, A.1    Bruni, G.2    Ardia, A.3    Sacchetti, G.4
  • 44
    • 0025009025 scopus 로고
    • A double-blind randomized study of two ergot derivatives in mild to moderate dementia
    • Battaglia A, Bruni G, Sacchetti G, Pamparana F, Nicergoline Cooperative Study Group. A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Current Therapeutic Research 1990;48:597-612.
    • (1990) Current Therapeutic Research , vol.48 , pp. 597-612
    • Battaglia, A.1    Bruni, G.2    Sacchetti, G.3    Pamparana, F.4
  • 46
    • 0028935334 scopus 로고
    • Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG/ERP mapping study
    • Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, and others. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995;117:385-95.
    • (1995) Psychopharmacology , vol.117 , pp. 385-395
    • Saletu, B.1    Paulus, E.2    Linzmayer, L.3    Anderer, P.4    Semlitsch, H.V.5    Grunberger, J.6
  • 47
    • 0015359233 scopus 로고
    • The clinical use of piracetam, a new nootropic drug: The treatment of symptoms of senile involutions
    • Stegink AJ. The clinical use of piracetam, a new nootropic drug: the treatment of symptoms of senile involutions. Arzneimittel-Forschung (Drug Research) 1972;22:975-7.
    • (1972) Arzneimittel-Forschung (Drug Research) , vol.22 , pp. 975-977
    • Stegink, A.J.1
  • 48
    • 0017168778 scopus 로고
    • Results with piracetam in the management of senile psycho-organic syndromes
    • Macchione C, Molaschi M, Fabris F, Feruglio FS. Results with piracetam in the management of senile psycho-organic syndromes. Acta Therapeutica 1976;2:261-9.
    • (1976) Acta Therapeutica , vol.2 , pp. 261-269
    • Macchione, C.1    Molaschi, M.2    Fabris, F.3    Feruglio, F.S.4
  • 49
    • 0017799197 scopus 로고
    • A double-blind investigation of piracetam (Nootropil) versus placebo in the memory of geriatric inpatients
    • Abuzzahab Sr FS, Merwin GE, Zimmermann RL, Sherman MC. A double-blind investigation of piracetam (Nootropil) versus placebo in the memory of geriatric inpatients. Psychopharmacol Bull 1978;14:23-5.
    • (1978) Psychopharmacol Bull , vol.14 , pp. 23-25
    • Abuzzahab Sr., F.S.1    Merwin, G.E.2    Zimmermann, R.L.3    Sherman, M.C.4
  • 51
    • 84984360979 scopus 로고
    • Cholinergic treatment in Alzheimer's disease: Implications for future research
    • Davis KL, Mohs RC, Davis BM, Levy MI, Horvath TB. Rosenberg GS, and others. Cholinergic treatment in Alzheimer's disease: implications for future research. Aging 1982;19:475-81.
    • (1982) Aging , vol.19 , pp. 475-481
    • Davis, K.L.1    Mohs, R.C.2    Davis, B.M.3    Levy, M.I.4    Horvath, T.B.5    Rosenberg, G.S.6
  • 52
    • 0011924105 scopus 로고
    • Pharmacologic treatment of senile dementia: Choline, 1-dopa, piracetam, and choline plus piracetam
    • Ferris SH, Reísberg B, Crook T, Friedman E, Schneck MK, Mir P, and others. Pharmacologic treatment of senile dementia: choline, 1-dopa, piracetam, and choline plus piracetam. Aging 1982;19:475-81.
    • (1982) Aging , vol.19 , pp. 475-481
    • Ferris, S.H.1    Reísberg, B.2    Crook, T.3    Friedman, E.4    Schneck, M.K.5    Mir, P.6
  • 53
    • 0020448412 scopus 로고
    • The effects of Oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam)
    • Itil TM, Menon GN, Bozak M, Songar A. The effects of Oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Development Research 1982;2:447-61.
    • (1982) Drug Development Research , vol.2 , pp. 447-461
    • Itil, T.M.1    Menon, G.N.2    Bozak, M.3    Songar, A.4
  • 56
    • 0021186748 scopus 로고
    • Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderly
    • Ferrero E. Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderly. Current Therapeutic Research 1984;36:298-308.
    • (1984) Current Therapeutic Research , vol.36 , pp. 298-308
    • Ferrero, E.1
  • 57
    • 0021857770 scopus 로고
    • Haemorheological pattern in initial mental deterioration: Results of a long-term study using piracetam and pentoxifyl-line
    • Parnetti L, Ciuffetti G, Mercuri M, Senin U. Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifyl-line. Archives of Gerontology & Geriatrics 1985;4:141-55.
    • (1985) Archives of Gerontology & Geriatrics , vol.4 , pp. 141-155
    • Parnetti, L.1    Ciuffetti, G.2    Mercuri, M.3    Senin, U.4
  • 58
    • 0022273985 scopus 로고
    • Clinical evaluation of compounds for the treatment of memory dysfunction
    • Growdon JH, Corkin S, Huff FJ. Clinical evaluation of compounds for the treatment of memory dysfunction. Ann N Y Acad Sci 1985;444:437-49.
    • (1985) Ann N Y Acad Sci , vol.444 , pp. 437-449
    • Growdon, J.H.1    Corkin, S.2    Huff, F.J.3
  • 59
    • 0022994947 scopus 로고
    • Piracetam combined with lecithin in the treatment of Alzheimer's disease
    • Growdon JH, Corkin S, Jacob F, Rosen TJ. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurology of Aging 1986;7:269-76.
    • (1986) Neurology of Aging , vol.7 , pp. 269-276
    • Growdon, J.H.1    Corkin, S.2    Jacob, F.3    Rosen, T.J.4
  • 61
    • 0026875343 scopus 로고
    • Moving from the question of efficacy to the question of therapeutic relevance: An exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam
    • Herrmann WM, Stephan K. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam. Int Psychogeriatr 1992;4:25-44.
    • (1992) Int Psychogeriatr , vol.4 , pp. 25-44
    • Herrmann, W.M.1    Stephan, K.2
  • 63
    • 0028061383 scopus 로고
    • Drug therapy and memory training programs: A double-blind randomized trial of general practice patients with age-assocíated memory impairment
    • Israel L, Melac M, Mílínkevitch D, Dubos G. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-assocíated memory impairment. International Psychogeriatrics 1994; 6:115-70.
    • (1994) International Psychogeriatrics , vol.6 , pp. 115-170
    • Israel, L.1    Melac, M.2    Mílínkevitch, D.3    Dubos, G.4
  • 66
    • 0024435052 scopus 로고
    • Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia
    • Dysken MW, Katz R, Stallone F, Kuskowski M. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. J Neuropsychíatry Clin Neurosci 1989;1:249-52.
    • (1989) J Neuropsychíatry Clin Neurosci , vol.1 , pp. 249-252
    • Dysken, M.W.1    Katz, R.2    Stallone, F.3    Kuskowski, M.4
  • 67
    • 0024827752 scopus 로고
    • Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: A double-blind, placebo-controlled study
    • Maina G, Fiori L, Torta R, Fagiani MB, Ravizza L, Bonavita E, and others. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 1989;21:141-5.
    • (1989) Neuropsychobiology , vol.21 , pp. 141-145
    • Maina, G.1    Fiori, L.2    Torta, R.3    Fagiani, M.B.4    Ravizza, L.5    Bonavita, E.6
  • 68
    • 0025200627 scopus 로고
    • Selegiline versus oxiracetam in patients with Alzheimer-type dementia
    • Falsaperla A, Preti PAM, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 1990;12:376-84.
    • (1990) Clin Ther , vol.12 , pp. 376-384
    • Falsaperla, A.1    Preti, P.A.M.2    Oliani, C.3
  • 69
    • 0027049547 scopus 로고
    • Effects of ìdebenone ín elderly subjects with cognitive decline: Results of a multicentre clinical trial
    • Bergamasco B, Villardita C, Coppi R. Effects of ìdebenone ín elderly subjects with cognitive decline: results of a multicentre clinical trial. Archives of Gerontology & Geriatrics 1992;15:279-86.
    • (1992) Archives of Gerontology & Geriatrics , vol.15 , pp. 279-286
    • Bergamasco, B.1    Villardita, C.2    Coppi, R.3
  • 72
    • 0026605434 scopus 로고
    • Clinical studies with oxiracetam inpatients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree
    • Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J. Clinical studies with oxiracetam inpatients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Neuropsychobiology 1992;25(1):24-8.
    • (1992) Neuropsychobiology , vol.25 , Issue.1 , pp. 24-28
    • Villardita, C.1    Grioli, S.2    Lomeo, C.3    Cattaneo, C.4    Parini, J.5
  • 73
    • 0027548555 scopus 로고
    • Treatment of cognitive impairment secondary to degenerative dementia: Effectiveness of oxiracetam therapy
    • Rozzini R, Zanetti O, Bianchetti A. Treatment of cognitive impairment secondary to degenerative dementia: effectiveness of oxiracetam therapy. Acta Neurologica 1993;15(1):44-52.
    • (1993) Acta Neurologica , vol.15 , Issue.1 , pp. 44-52
    • Rozzini, R.1    Zanetti, O.2    Bianchetti, A.3
  • 74
    • 0021678374 scopus 로고
    • Effects of aniracetam, a nootropic drug, in senile dementia - A preliminary report
    • Mizuki Y, Yamada M, Kato I, Takada Y, Tsujimaru S, Inanaga K, and others. Effects of aniracetam, a nootropic drug, in senile dementia - a preliminary report. Kurume Med J 1984;31:135-43.
    • (1984) Kurume Med J , vol.31 , pp. 135-143
    • Mizuki, Y.1    Yamada, M.2    Kato, I.3    Takada, Y.4    Tsujimaru, S.5    Inanaga, K.6
  • 75
    • 0023147444 scopus 로고
    • Senile dementia of the Alzheimer type treated with aniracetam: A new nootropic agent
    • Sourander LB, Portin R, Molsa P, Lahdes A, Rinne UK. Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. Psychopharmacology 1987;91:90-5.
    • (1987) Psychopharmacology , vol.91 , pp. 90-95
    • Sourander, L.B.1    Portin, R.2    Molsa, P.3    Lahdes, A.4    Rinne, U.K.5
  • 77
    • 0025730734 scopus 로고
    • Nootropic drugs in Alzheimer's disease: Symptomatic treatment with pramiracetam
    • Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 1991;41:570-4.
    • (1991) Neurology , vol.41 , pp. 570-574
    • Claus, J.J.1    Ludwig, C.2    Mohr, E.3    Giuffra, M.4    Blin, J.5    Chase, T.N.6
  • 78
    • 0027157131 scopus 로고
    • Responders and non-responders to bifemelane hydrochloride in Alzheimer-type and multi-infarct dementia
    • Shigeta M, Nishikawa Y, Shimìzu M, Usui M, Hyoki K, Kawamuro Y. Responders and non-responders to bifemelane hydrochloride in Alzheimer-type and multi-infarct dementia. Int Clin Psychopharmacol 1993;8:109-14.
    • (1993) Int Clin Psychopharmacol , vol.8 , pp. 109-114
    • Shigeta, M.1    Nishikawa, Y.2    Shimìzu, M.3    Usui, M.4    Hyoki, K.5    Kawamuro, Y.6
  • 79
    • 0024334912 scopus 로고
    • Gerontopsychological studies using NAI ("Nurnberger Alters-Inventar") on patients with organic psychosyndrome (DSM-III, category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial
    • Pek G, Fulop T, Zs-Nagy I. Gerontopsychological studies using NAI ("Nurnberger Alters-Inventar") on patients with organic psychosyndrome (DSM-III, category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Archives of Gerontology & Geriatrics 1989;9:17-30.
    • (1989) Archives of Gerontology & Geriatrics , vol.9 , pp. 17-30
    • Pek, G.1    Fulop, T.2    Zs-Nagy, I.3
  • 80
    • 0025533420 scopus 로고
    • Propentofylline in adult-onset cognitive disorders: Double-blind, placebo-controlled, clinical, psychometric and brain mapping studies
    • Saletu B, Moller HJ, Grunberger J, Deutsch H, Rossner M. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 1990;24(4):173-84.
    • (1990) Neuropsychobiology , vol.24 , Issue.4 , pp. 173-184
    • Saletu, B.1    Moller, H.J.2    Grunberger, J.3    Deutsch, H.4    Rossner, M.5
  • 81
    • 0028236476 scopus 로고
    • Placebo-controlled trial of the xanthíne derivative propentofylline in dementia
    • Moller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthíne derivative propentofylline in dementia. Pharmacopsychiatry 1994;27:159-65.
    • (1994) Pharmacopsychiatry , vol.27 , pp. 159-165
    • Moller, H.J.1    Maurer, I.2    Saletu, B.3
  • 83
    • 0022538062 scopus 로고
    • On the effects of pyritinol on functional deficits of patients with organic mental disorders
    • Hermann WM, Kern U, Rohmel J. On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry 1986;19:378-85.
    • (1986) Pharmacopsychiatry , vol.19 , pp. 378-385
    • Hermann, W.M.1    Kern, U.2    Rohmel, J.3
  • 84
    • 0024379593 scopus 로고
    • Pyritinol treatment of SDAT patients: Evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements
    • Knezevic S, Mubrin Z, Risberg J, Vucinic G, Spilich G, Gubarev N, and others. Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Int Clin Psychopharmacol 1989;4:25-38.
    • (1989) Int Clin Psychopharmacol , vol.4 , pp. 25-38
    • Knezevic, S.1    Mubrin, Z.2    Risberg, J.3    Vucinic, G.4    Spilich, G.5    Gubarev, N.6
  • 85
    • 0026499718 scopus 로고
    • Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID)
    • Fischhof PK, Saletu B, Ruther E, Litschauer G, Moslinger-Gehmayr R, Herrmann WM. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 1992;26:65-70.
    • (1992) Neuropsychobiology , vol.26 , pp. 65-70
    • Fischhof, P.K.1    Saletu, B.2    Ruther, E.3    Litschauer, G.4    Moslinger-Gehmayr, R.5    Herrmann, W.M.6
  • 86
    • 0027335645 scopus 로고
    • Effects of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects
    • Allain H, Raoul P, Lieury A, LeCoz F, Gandon J. Effects of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549-58.
    • (1993) Clin Ther , vol.15 , pp. 549-558
    • Allain, H.1    Raoul, P.2    Lieury, A.3    LeCoz, F.4    Gandon, J.5
  • 87
  • 93
    • 0013572641 scopus 로고
    • Therapeutic potential of thyrotropin-releasing hormone (TRH) and lecithin co-administration in Alzheimer's disease
    • Lampe TH, Norris J, Risse SC, Owen-Williams E, Keenan T. Therapeutic potential of thyrotropin-releasing hormone (TRH) and lecithin co-administration in Alzheimer's disease [abstract]. Neurobiol Aging 1990;11:346.
    • (1990) Neurobiol Aging , vol.11 , pp. 346
    • Lampe, T.H.1    Norris, J.2    Risse, S.C.3    Owen-Williams, E.4    Keenan, T.5
  • 95
    • 0022525677 scopus 로고
    • Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
    • Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, and others. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-45.
    • (1986) Psychoneuroendocrinology , vol.11 , pp. 337-345
    • Fillit, H.1    Weinreb, H.2    Cholst, I.3    Luine, V.4    McEwen, B.5    Amador, R.6
  • 96
    • 0019363538 scopus 로고
    • Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia
    • Christie JE, Shering A, Ferguson J, Glen AIM. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981;138:46-50.
    • (1981) Br J Psychiatry , vol.138 , pp. 46-50
    • Christie, J.E.1    Shering, A.2    Ferguson, J.3    Glen, A.I.M.4
  • 97
    • 0019949485 scopus 로고
    • Enhancements of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine
    • Davis KL, Mohs RC. Enhancements of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139:1421-4.
    • (1982) Am J Psychiatry , vol.139 , pp. 1421-1424
    • Davis, K.L.1    Mohs, R.C.2
  • 99
    • 0022230177 scopus 로고
    • Efficacy of oral physostigmine in primary degenerative dementia
    • Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia. Psychopharmacology 1985;87:147-51.
    • (1985) Psychopharmacology , vol.87 , pp. 147-151
    • Beller, S.A.1    Overall, J.E.2    Swann, A.C.3
  • 100
    • 0023197078 scopus 로고
    • Effects of oral physostigmine in Alzheimer's disease
    • Stern Y, Sano M, Mayeux R. Effects of oral physostigmine in Alzheimer's disease. Ann Neurol 1987;22:306-10.
    • (1987) Ann Neurol , vol.22 , pp. 306-310
    • Stern, Y.1    Sano, M.2    Mayeux, R.3
  • 101
    • 0023761106 scopus 로고
    • Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia
    • Neshige R, Barrett G. Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia. J Neurol Neurosurg Psychiatry 1988;51:1120-5.
    • (1988) J Neurol Neurosurg Psychiatry , vol.51 , pp. 1120-1125
    • Neshige, R.1    Barrett, G.2
  • 102
    • 0025074779 scopus 로고
    • The effect of long-term physostigmine administration in Alzheimer's disease
    • Harrell LE, Callaway R, Morere D, Falgout J. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990;40:1350-4.
    • (1990) Neurology , vol.40 , pp. 1350-1354
    • Harrell, L.E.1    Callaway, R.2    Morere, D.3    Falgout, J.4
  • 104
    • 0027396643 scopus 로고
    • Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease
    • Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Clin Neuropharmacol 1993;16(1):61-9.
    • (1993) Clin Neuropharmacol , vol.16 , Issue.1 , pp. 61-69
    • Sano, M.1    Bell, K.2    Marder, K.3    Stricks, L.4    Stern, Y.5    Mayeux, R.6
  • 107
    • 0020032644 scopus 로고
    • Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia
    • Caltagìrone C, Gainotti G, Masulo C. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 1982;16:247-9.
    • (1982) Int J Neurosci , vol.16 , pp. 247-249
    • Caltagìrone, C.1    Gainotti, G.2    Masulo, C.3
  • 108
    • 0028284299 scopus 로고
    • Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy
    • Litvan I, Blesa R, Clark K, Nichelli P, Atack JR, Mouradian MM, and others. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55-61.
    • (1994) Ann Neurol , vol.36 , pp. 55-61
    • Litvan, I.1    Blesa, R.2    Clark, K.3    Nichelli, P.4    Atack, J.R.5    Mouradian, M.M.6
  • 110
    • 0028316959 scopus 로고
    • Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
    • Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
    • (1994) JAMA , vol.271 , pp. 992-998
    • Watkins, P.B.1    Zimmerman, H.J.2    Knapp, M.J.3    Gracon, S.I.4    Lewis, K.W.5
  • 111
    • 0030449513 scopus 로고    scopus 로고
    • Bíoavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease
    • Lou G, Montgomery PR, Sitar DS. Bíoavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. J Psychiatry Neurosci 1996;21:334-9.
    • (1996) J Psychiatry Neurosci , vol.21 , pp. 334-339
    • Lou, G.1    Montgomery, P.R.2    Sitar, D.S.3
  • 112
    • 0022899577 scopus 로고
    • Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
    • Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.
    • (1986) N Engl J Med , vol.315 , pp. 1241-1245
    • Summers, W.K.1    Majovski, L.V.2    Marsh, G.M.3    Tachiki, K.4    Kling, A.5
  • 113
    • 0025247740 scopus 로고
    • Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial
    • Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ 1990;300:495-9.
    • (1990) BMJ , vol.300 , pp. 495-499
    • Chatellier, G.1    Lacomblez, L.2
  • 114
    • 0025312142 scopus 로고
    • Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease
    • Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, and others. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990;322:1272-6.
    • (1990) N Engl J Med , vol.322 , pp. 1272-1276
    • Gauthier, S.1    Bouchard, R.2    Lamontagne, A.3    Bailey, P.4    Bergman, H.5    Ratner, J.6
  • 115
  • 116
    • 0026756286 scopus 로고
    • A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
    • Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, and others. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
    • (1992) N Engl J Med , vol.327 , pp. 1253-1259
    • Davis, K.L.1    Thal, L.J.2    Gamzu, E.R.3    Davis, C.S.4    Woolson, R.F.5    Gracon, S.I.6
  • 118
    • 0027512824 scopus 로고
    • Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG
    • Mìnthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, and others. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42.
    • (1993) Dementia , vol.4 , pp. 32-42
    • Mìnthon, L.1    Gustafson, L.2    Dalfelt, G.3    Hagberg, B.4    Nilsson, K.5    Risberg, J.6
  • 119
    • 0027719699 scopus 로고
    • Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy
    • Alhainen K, Riekkinen PJ Sr. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand 1993; Suppl 149:16S-21S.
    • (1993) Acta Neurol Scand , Issue.149 SUPPL.
    • Alhainen, K.1    Riekkinen Sr., P.J.2
  • 120
    • 0027214653 scopus 로고
    • An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease
    • Wilcock GK, Surmon DJ, Scott M, Boyle M, Mulligan K, Neubauer KA, and others. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing 1993;22:316-24.
    • (1993) Age Ageing , vol.22 , pp. 316-324
    • Wilcock, G.K.1    Surmon, D.J.2    Scott, M.3    Boyle, M.4    Mulligan, K.5    Neubauer, K.A.6
  • 121
    • 0028270519 scopus 로고
    • A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
    • Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
    • (1994) JAMA , vol.271 , pp. 985-991
    • Knapp, M.J.1    Knopman, D.S.2    Solomon, P.R.3    Pendlebury, W.W.4    Davis, C.S.5    Gracon, S.I.6
  • 122
    • 0028175439 scopus 로고
    • Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: Double blind trial
    • Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ 1994;308:879-83.
    • (1994) BMJ , vol.308 , pp. 879-883
    • Maltby, N.1    Broe, G.A.2    Creasey, H.3    Jorm, A.F.4    Christensen, H.5    Brooks, W.S.6
  • 123
    • 0030035653 scopus 로고    scopus 로고
    • Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
    • Knopman D, Schneider L, Davis K, Talwalker, Smith F, Hoover T, and others. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
    • (1996) Neurology , vol.47 , pp. 166-177
    • Knopman, D.1    Schneider, L.2    Davis, K.3    Talwalker4    Smith, F.5    Hoover, T.6
  • 124
    • 0027165554 scopus 로고
    • The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease
    • Alhainen K, Helkala EL, Reinikainen K, Riekkinen P Sr. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1993;5:185-92.
    • (1993) J Neural Transm Park Dis Dement Sect , vol.5 , pp. 185-192
    • Alhainen, K.1    Helkala, E.L.2    Reinikainen, K.3    Riekkinen Sr., P.4
  • 125
    • 0026687684 scopus 로고
    • Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease
    • Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, and others. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 1992;108:103-9.
    • (1992) Psychopharmacology , vol.108 , pp. 103-109
    • Kp, E.1    Hunter, R.2    Curran, S.M.3    Dougal, N.J.4    Murray, C.L.5    Wyper, D.J.6
  • 126
    • 0029143531 scopus 로고
    • Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled study
    • Antuono PG and the Mentane Study Group. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled study. Arch Intern Med 1995;155:1766-72.
    • (1995) Arch Intern Med , vol.155 , pp. 1766-1772
    • Antuono, P.G.1
  • 127
    • 0029924782 scopus 로고    scopus 로고
    • Double-blind placebo-controlled study of velnacrine in Alzheimer's disease
    • Zemlan FP, Keys M, Richter RW, Strub RL. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Life Sci 1996;58:1823-32.
    • (1996) Life Sci , vol.58 , pp. 1823-1832
    • Zemlan, F.P.1    Keys, M.2    Richter, R.W.3    Strub, R.L.4
  • 128
    • 10244259208 scopus 로고    scopus 로고
    • The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
    • Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
    • (1996) Dementia , vol.7 , pp. 293-303
    • Rogers, S.L.1    Friedhoff, L.T.2
  • 129
    • 0027563450 scopus 로고
    • Multicentre study of 1-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type
    • Parnetti L, Abate G, Bartorelli L, Cucinotta D, Cuzzupoli M, Maggioni M, and others. Multicentre study of 1-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Drugs & Aging 1993;3:159-64.
    • (1993) Drugs & Aging , vol.3 , pp. 159-164
    • Parnetti, L.1    Abate, G.2    Bartorelli, L.3    Cucinotta, D.4    Cuzzupoli, M.5    Maggioni, M.6
  • 130
    • 0021242464 scopus 로고
    • Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease
    • Smith RC, Vroulis G, Johnson R, Morgan R. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol Bull 1984;20:542-5.
    • (1984) Psychopharmacol Bull , vol.20 , pp. 542-545
    • Smith, R.C.1    Vroulis, G.2    Johnson, R.3    Morgan, R.4
  • 131
    • 0028351522 scopus 로고
    • Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease
    • Caamano J, Gomez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol 1994;16:211-8.
    • (1994) Methods Find Exp Clin Pharmacol , vol.16 , pp. 211-218
    • Caamano, J.1    Gomez, M.J.2    Franco, A.3    Cacabelos, R.4
  • 135
    • 0022628875 scopus 로고
    • Muscarinic agonist therapy of Alzheimer's disease: A clinical trial of RS-86
    • Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease: a clinical trial of RS-86. Arch Neurol 1986;43:659-61.
    • (1986) Arch Neurol , vol.43 , pp. 659-661
    • Bruno, G.1    Mohr, E.2    Gillespie, M.3    Fedio, P.4    Chase, T.N.5
  • 136
    • 0028937797 scopus 로고
    • Linopirdine: A depolarization-activated releaser of transmitters for treatment of dementia
    • Tarn SW, Zaczek R. Linopirdine: a depolarization-activated releaser of transmitters for treatment of dementia. Adv Exp Med Biol 1995;363:47-56.
    • (1995) Adv Exp Med Biol , vol.363 , pp. 47-56
    • Tarn, S.W.1    Zaczek, R.2
  • 137
    • 0029073717 scopus 로고
    • Posatirelin for the treatment of late-onset Alzheimer's disease: A double-blind multicentre study vs citicoline and ascorbic acid
    • Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bartorelli L, and others. Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 1995;92:135-40.
    • (1995) Acta Neurol Scand , vol.92 , pp. 135-140
    • Parnetti, L.1    Ambrosoli, L.2    Abate, G.3    Azzini, C.4    Balestreri, R.5    Bartorelli, L.6
  • 138
    • 0029962164 scopus 로고    scopus 로고
    • Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease
    • Huff FJ and the Besipirdine Study Group. Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Ann N Y Acad Sci 1996;777:410-4.
    • (1996) Ann N Y Acad Sci , vol.777 , pp. 410-414
    • Huff, F.J.1
  • 140
    • 0025304847 scopus 로고
    • Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia
    • Piccinin GL, Finali G, Massimo P. Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990;13:147-63.
    • (1990) Clin Neuropharmacol , vol.13 , pp. 147-163
    • Piccinin, G.L.1    Finali, G.2    Massimo, P.3
  • 148
    • 0021955314 scopus 로고
    • A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia
    • Dehlin O, Hedenrud B, Jansson P, Norgard J. A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand 1985;71:190-6.
    • (1985) Acta Psychiatr Scand , vol.71 , pp. 190-196
    • Dehlin, O.1    Hedenrud, B.2    Jansson, P.3    Norgard, J.4
  • 151
    • 0021338328 scopus 로고
    • Combined piracetam and cholinergic precursor treatment for primary degenerative dementia
    • Pomara N, Block R, Moore N, Rhiew HB, Berchou R, Stanley M, and others. Combined piracetam and cholinergic precursor treatment for primary degenerative dementia. IRCS Medical Science 1984;12:388-9.
    • (1984) IRCS Medical Science , vol.12 , pp. 388-389
    • Pomara, N.1    Block, R.2    Moore, N.3    Rhiew, H.B.4    Berchou, R.5    Stanley, M.6
  • 152
    • 0027406164 scopus 로고
    • A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease
    • Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 1993;150:321-3.
    • (1993) Am J Psychiatry , vol.150 , pp. 321-323
    • Schneider, L.S.1    Olin, J.T.2    Pawluczyk, S.3
  • 154
    • 0029886801 scopus 로고    scopus 로고
    • Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
    • Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
    • (1996) Neurology , vol.46 , pp. 1580-1584
    • Schneider, L.S.1    Farlow, M.R.2    Henderson, V.W.3    Pogoda, J.M.4
  • 155
  • 156
    • 0027745626 scopus 로고
    • NGF and the treatment of Alzheimer's disease
    • Olson L. NGF and the treatment of Alzheimer's disease. Exp Neurol 1993;124:5-15.
    • (1993) Exp Neurol , vol.124 , pp. 5-15
    • Olson, L.1
  • 157
    • 0029904388 scopus 로고    scopus 로고
    • Neurotrophins and Alzheìmer's disease: Beyond the cholinergic neurons
    • Knusel B, Gao H. Neurotrophins and Alzheìmer's disease: beyond the cholinergic neurons. Life Sci 1996;58:2019-27.
    • (1996) Life Sci , vol.58 , pp. 2019-2027
    • Knusel, B.1    Gao, H.2
  • 158
    • 0001867754 scopus 로고
    • Conventional pharmacologic treatment for patients with Alzheimer's disease
    • Gottlieb GL, Kumar A. Conventional pharmacologic treatment for patients with Alzheimer's disease. Neurology 1993;43(4 Suppl):56S-63S.
    • (1993) Neurology , vol.43 , Issue.4 SUPPL.
    • Gottlieb, G.L.1    Kumar, A.2
  • 160
    • 0026403940 scopus 로고
    • Acetyl-1-carnitine: A drug able to slow the progress of Alzheimer's disease?
    • Carta A, Calvani M. Acetyl-1-carnitine: a drug able to slow the progress of Alzheimer's disease? Ann N Y Acad Sci 1991;640:228-32.
    • (1991) Ann N Y Acad Sci , vol.640 , pp. 228-232
    • Carta, A.1    Calvani, M.2
  • 161
    • 0007550585 scopus 로고
    • Pharmacological management and treatment of dementia and secondary symptoms
    • Weiner MF, editor. Washington (DC): American Psychiatric Press
    • Weiner MF, Debus JR, Goodkin K, Pharmacological management and treatment of dementia and secondary symptoms. In: Weiner MF, editor. The dementias: diagnosis and management. Washington (DC): American Psychiatric Press; 1991. p 135-66.
    • (1991) The Dementias: Diagnosis and Management , pp. 135-166
    • Weiner, M.F.1    Debus, J.R.2    Goodkin, K.3
  • 162
    • 0027151789 scopus 로고
    • Clinical aspects of nimodipine
    • 18th CINP Congress Satellite Symposium: Calcium homeostasis and brain function: pharmacological rationale and clinical implications (1992, Nice, France)
    • Grobe-Einsler R. Clinical aspects of nimodipine. 18th CINP Congress Satellite Symposium: Calcium homeostasis and brain function: pharmacological rationale and clinical implications (1992, Nice, France), Clin Neuropharmacol 1993; 16(1 Suppl):39S-45S.
    • (1993) Clin Neuropharmacol , vol.16 , Issue.1 SUPPL.
    • Grobe-Einsler, R.1
  • 163
    • 0026481585 scopus 로고
    • Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes
    • Schmage N, Bergener M. Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int Psychogeriatr 1992; 4(1 Suppl):89S-99S.
    • (1992) Int Psychogeriatr , vol.4 , Issue.1 SUPPL.
    • Schmage, N.1    Bergener, M.2
  • 164
    • 0028874179 scopus 로고
    • Therapeutic approaches for memory impairments
    • Hock FJ. Therapeutic approaches for memory impairments. Behav Brain Res 1995;66:143-50.
    • (1995) Behav Brain Res , vol.66 , pp. 143-150
    • Hock, F.J.1
  • 166
    • 0020558130 scopus 로고
    • The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia
    • Branconnier RJ. The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia. Psychopharmacol Bull 1983;19:212-9.
    • (1983) Psychopharmacol Bull , vol.19 , pp. 212-219
    • Branconnier, R.J.1
  • 167
    • 25844485515 scopus 로고
    • Nootropics
    • Reisberg R, editor. New York: Free Press
    • Schneck MK. Nootropics, In: Reisberg R, editor. Nootropics in Alzheimer's disease. New York: Free Press; 1983. p 362-8.
    • (1983) Nootropics in Alzheimer's Disease , pp. 362-368
    • Schneck, M.K.1
  • 168
    • 0020629538 scopus 로고
    • "Cerebroactive" drugs: Clinical pharmacology and therapeutic role in cerebrovascular disorders
    • Spagnoli A, Tognoni G. "Cerebroactive" drugs: clinical pharmacology and therapeutic role in cerebrovascular disorders. Drugs 1983;26:44-69.
    • (1983) Drugs , vol.26 , pp. 44-69
    • Spagnoli, A.1    Tognoni, G.2
  • 169
    • 1842404583 scopus 로고
    • Nootropic rugs in dementia: Preclinical prospects and clinical lessons
    • Katz RJ. Nootropic rugs in dementia: preclinical prospects and clinical lessons. Animal Models in Psychiatric Disorders 1988;1:175-88.
    • (1988) Animal Models in Psychiatric Disorders , vol.1 , pp. 175-188
    • Katz, R.J.1
  • 170
    • 0025332303 scopus 로고
    • Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia
    • Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990;101:147-59.
    • (1990) Psychopharmacology , vol.101 , pp. 147-159
    • Nicholson, C.D.1
  • 171
    • 0025718364 scopus 로고
    • Piracetam: An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders
    • Vernon MW, Sorkin EM. Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs & Aging 1991;1:17-35.
    • (1991) Drugs & Aging , vol.1 , pp. 17-35
    • Vernon, M.W.1    Sorkin, E.M.2
  • 172
    • 0026093863 scopus 로고
    • Multi-infarct dementia: Prevention and treatment
    • Wade JPH. Multi-infarct dementia: prevention and treatment. Alzheimer Dis Assoc Disord 1991;5:144-8.
    • (1991) Alzheimer Dis Assoc Disord , vol.5 , pp. 144-148
    • Wade, J.P.H.1
  • 174
    • 0017170501 scopus 로고
    • An ergot alkaloid preparation (Hydergine) in the treatment of dementia: Critical review of the clinical literature
    • Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc 1976;24;490-7.
    • (1976) J Am Geriatr Soc , vol.24 , pp. 490-497
    • Hughes, J.R.1    Williams, J.G.2    Currier, R.D.3
  • 175
    • 0018712497 scopus 로고
    • Hydergine: A review of 26 clinical studies
    • McDonald RJ. Hydergine: a review of 26 clinical studies. Pharmacopsychiatry 1979;12:407-22.
    • (1979) Pharmacopsychiatry , vol.12 , pp. 407-422
    • McDonald, R.J.1
  • 176
    • 0029875457 scopus 로고    scopus 로고
    • HWa 285 (propentofylline) - A new compound for the treatment of both vascular dementia and dementia of the Alzheimer type
    • Rother M, Kittner B, Rudolph K, Robner M, Labs KH. HWA 285 (propentofylline) - a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Ann N Y Acad Sci 1996;777:404-9.
    • (1996) Ann N Y Acad Sci , vol.777 , pp. 404-409
    • Rother, M.1    Kittner, B.2    Rudolph, K.3    Robner, M.4    Labs, K.H.5
  • 177
    • 0026408120 scopus 로고
    • Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia
    • Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann N Y Acad Sci 1991;640:237-40.
    • (1991) Ann N Y Acad Sci , vol.640 , pp. 237-240
    • Herting, R.L.1
  • 178
    • 0019972810 scopus 로고
    • The cholinergic hypothesis of geriatric memory dysfunction
    • Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
    • (1982) Science , vol.217 , pp. 408-417
    • Bartus, R.T.1    Dean III, R.L.2    Beer, B.3    Lippa, A.S.4
  • 179
    • 0026702524 scopus 로고
    • The implication of current therapeutic approaches for the cholinergic hypothesis of dementia
    • Traub M, Freedman SB. The implication of current therapeutic approaches for the cholinergic hypothesis of dementia. Dementia 1992;3:189-92.
    • (1992) Dementia , vol.3 , pp. 189-192
    • Traub, M.1    Freedman, S.B.2
  • 180
    • 0027240047 scopus 로고
    • New Alzheimer's drug expands your options in symptom management
    • Wolf-Klein GP. New Alzheimer's drug expands your options in symptom management. Geriatrics 1993;48(8):26-9.
    • (1993) Geriatrics , vol.48 , Issue.8 , pp. 26-29
    • Wolf-Klein, G.P.1
  • 181
    • 0028448282 scopus 로고
    • Tacrine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease
    • Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs & Aging 1994;4:510-40.
    • (1994) Drugs & Aging , vol.4 , pp. 510-540
    • Wagstaff, A.J.1    McTavish, D.2
  • 182
    • 0029160650 scopus 로고
    • Therapeutic trials in Alzheimer's disease
    • Whitehouse PJ, Voci J. Therapeutic trials in Alzheimer's disease. Curr Opin Neurol 1995;8:275-8.
    • (1995) Curr Opin Neurol , vol.8 , pp. 275-278
    • Whitehouse, P.J.1    Voci, J.2
  • 183
    • 0028198828 scopus 로고
    • Tacrine: First drug approved for Alzheimer's disease
    • Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994;28:744-51.
    • (1994) Ann Pharmacother , vol.28 , pp. 744-751
    • Crismon, M.L.1
  • 184
    • 0027969027 scopus 로고
    • Tacrine therapy for the dementia of Alzheimer's disease
    • Manning FC. Tacrine therapy for the dementia of Alzheimer's disease. Am Fam Physician 1994;50:819-26.
    • (1994) Am Fam Physician , vol.50 , pp. 819-826
    • Manning, F.C.1
  • 185
    • 0029013785 scopus 로고
    • THA-historical aspects, review of pharmacological properties and therapeutic effects
    • Soares JC, Gershon S. THA-historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995;6:225-34.
    • (1995) Dementia , vol.6 , pp. 225-234
    • Soares, J.C.1    Gershon, S.2
  • 186
    • 0027748339 scopus 로고
    • Pharmacodynamic and early clinical studies with velnacrine
    • Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand 1993;149(9 Suppl):26S-28S.
    • (1993) Acta Neurol Scand , vol.149 , Issue.9 SUPPL.
    • Siegfried, K.R.1
  • 187
    • 0028590052 scopus 로고
    • Therapy with 1-deprenyl (selegilíne) and relation to abuse liability
    • Schneider LS, Tariot PN, Goldstein B. Therapy with 1-deprenyl (selegilíne) and relation to abuse liability. Clin Pharmacol Ther 1994;56:750-6.
    • (1994) Clin Pharmacol Ther , vol.56 , pp. 750-756
    • Schneider, L.S.1    Tariot, P.N.2    Goldstein, B.3
  • 188
    • 0027323369 scopus 로고
    • Noradrenergic modulation of cognitive function: Clinical implications of anatomical, electrophysiological and behavioural studies in animal models
    • Berridge CW, Arnsten AF, Foote SL. Noradrenergic modulation of cognitive function: clinical implications of anatomical, electrophysiological and behavioural studies in animal models. Psychol Med 1993;23:557-64.
    • (1993) Psychol Med , vol.23 , pp. 557-564
    • Berridge, C.W.1    Arnsten, A.F.2    Foote, S.L.3
  • 189
    • 0029086845 scopus 로고
    • Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia
    • Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 1995;28:113-24.
    • (1995) Pharmacopsychiatry , vol.28 , pp. 113-124
    • Muller, W.E.1    Mutschler, E.2    Riederer, P.3
  • 190
    • 0029849263 scopus 로고
    • Transcranial magnetic stimulation: A neuropsychiatric tool for the 21st century
    • George MS, Wassermann EM, Post RM. Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J Neuropsychiatry Clin Neurosci 1966;8:373-82.
    • (1966) J Neuropsychiatry Clin Neurosci , vol.8 , pp. 373-382
    • George, M.S.1    Wassermann, E.M.2    Post, R.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.